ARTA
RYTM icon

A.R.T. Advisors’s Rhythm Pharmaceuticals RYTM Stock Holding History

A.R.T. Advisors’s Portfolio RYTM Stock Details RYTM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-18,057
Closed -$415K – 806
2019
Q4 		$415K Buy
18,057
+6,600
+58% +$147K 0.02% 916
2019
Q3 		$247K Buy
+11,457
New +$246K 0.01% 1127

Other funds holding RYTM

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

A.R.T. Advisors's RYTM Position: Q1 2020 in Review

A.R.T. Advisors sold out of Rhythm Pharmaceuticals (RYTM) in Q1 2020, closing a stake of 18,057 shares — an estimated $415K sold.

A.R.T. Advisors first reported a position in RYTM in Q3 2019 and held it in 2 quarters. The position peaked at $415K in Q4 2019. 80 funds tracked by Wall St. Rank hold RYTM as of Q1 2020.

  • A.R.T. Advisors reported no remaining Rhythm Pharmaceuticals position as of Q1 2020 after selling out during the quarter.
  • A.R.T. Advisors sold 18,057 Rhythm Pharmaceuticals shares in Q1 2020, an estimated $415K.
  • A.R.T. Advisors first reported a position in Rhythm Pharmaceuticals in Q3 2019 and held it in 2 quarters.
  • A.R.T. Advisors's Rhythm Pharmaceuticals position peaked at $415K in Q4 2019.
  • 80 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q1 2020.

Based on A.R.T. Advisors's 13F filing for Q1 2020, filed 15 May 2020.